Evidence map›Paper›PMID 34510793›Full record

ArticleCPT: pharmacometrics & systems pharmacology2021

CKD subpopulations defined by risk-factors: A longitudinal analysis of electronic health records.

Rajagopalan Ramaswamy, Soon Nan Wee, Kavya George, Abhijit Ghosh, Joydeep Sarkar, Rolf Burghaus, Jörg Lippert

Open access · goldAbstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Rajagopalan RamaswamyAdvanced Analytics, Holmusk, Singapore.
Soon Nan WeeAdvanced Analytics, Holmusk, Singapore.
Kavya GeorgeAdvanced Analytics, Holmusk, Singapore.
Abhijit GhoshAdvanced Analytics, Holmusk, Singapore.
Joydeep SarkarAdvanced Analytics, Holmusk, Singapore.
Rolf BurghausPharmacometrics, Bayer AG - Pharmaceuticals, Wuppertal, Germany.
Jörg LippertPharmacometrics, Bayer AG - Pharmaceuticals, Wuppertal, Germany.
Advanced Digital Sciences Center · SGBayer (Germany) · DE

Funding

Bayer
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a progressive disease that evades early detection and is associated with various comorbidities. Although clinical comprehension and control of these comorbidities is crucial for CKD management, complex pathophysiological interactions and feedback loops make this a formidable task. We have developed a hybrid semimechanistic modeling methodology to investigate CKD progression. The model is represented as a system of ordinary differential equations with embedded neural networks and takes into account complex disease progression pathways, feedback loops, and effects of 53 medications to generate time trajectories of eight clinical biomarkers that capture CKD progression due to various risk factors. The model was applied to real world data of US patients with CKD to map the available longitudinal information onto a set of time-invariant patient-specific parameters with a clear biological interpretation. These parameters describing individual patients were used to segment the cohort using a clustering approach. Model-based simulations were conducted to investigate cluster-specific treatment strategies. The model was able to reliably reproduce the variability in biomarkers across the cohort. The clustering procedure segmented the cohort into five subpopulations - four with enhanced sensitivity to a specific risk factor (hypertension, hyperlipidemia, hyperglycemia, or impaired kidney) and one that is largely insensitive to any of the risk factors. Simulation studies were used to identify patient-specific strategies to restrain or prevent CKD progression through management of specific risk factors. The semimechanistic model enables identification of disease progression phenotypes using longitudinal data that aid in prioritizing treatment strategies at individual patient level.

Indexed as

Electronic Health RecordsRenal Insufficiency, ChronicCohort StudiesComorbidityDisease ProgressionHumansRisk Factors

Identifiers

PMID34510793
PMCPMC8592509
OpenAlexW3201364505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.